A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Extended safety profile of oral clodronate after long-term use in primary breast cancer patients
Tekijät: Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J
Kustantaja: ADIS INTERNATIONAL LTD
Julkaisuvuosi: 2003
Lehti:: Drug Safety
Tietokannassa oleva lehden nimi: DRUG SAFETY
Lehden akronyymi: DRUG SAFETY
Vuosikerta: 26
Numero: 9
Aloitussivu: 661
Lopetussivu: 671
Sivujen määrä: 11
ISSN: 0114-5916
DOI: https://doi.org/10.2165/00002018-200326090-00005
Tiivistelmä
Conclusion: These results indicate that in women with early breast cancer receiving adjuvant systemic therapy, oral clodronate for 2 years is generally well tolerated with no serious long-term sequelae, providing a safe, long-term therapy in the adjuvant setting.
Conclusion: These results indicate that in women with early breast cancer receiving adjuvant systemic therapy, oral clodronate for 2 years is generally well tolerated with no serious long-term sequelae, providing a safe, long-term therapy in the adjuvant setting.